I'll be quick.
Yes, what Dr. Nadler says is true, but we do know that the size and the nodal status still matter even for aggressive tumours. In fact, sometimes it matters even more. As I said, the five-year survival rate for stage one triple-negative cancer is 96%. Stage 3 is 47%.
We also use modelling. It's not all about anecdotal cases of some women who didn't benefit. It's true that not all women will benefit to the same extent as others, but if you don't screen, you don't find the cancer in the first place to know whether it is high grade or not.